Project Grant R41DK131681
Award Date
9/17/21
Completion Date
8/31/23
Dollars Obligated
$926K
Similar Awards
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $740,040 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Xylyx Bio, Inc. The grant supports the development and validation of a liver fibrosis cell-based assay platform containing engineered human liver fibrotic lesions. This platform integrates patient-derived stellate cells, Kupffer cells, and hepatocytes within standardized human fibrotic liver...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is funding Faknostics LLC's research and development of novel peptidic inhibitors targeting the paxillin-FAK interaction for the treatment of liver fibrosis. The $651,952 award will enable Faknostics to optimize lead peptide candidates, characterize their activity in vitro, and confirm efficacy in...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Fibrotherapeutics Inc. a $675,480 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a novel therapeutic for chronic kidney disease (CKD). The grant aims to advance a modified, water-soluble, orally-active caveolin-1 scaffolding domain (CSD) peptide as a potential treatment for CKD. Key objectives include determining the therapeutic index of...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $272,964 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The award, effective August 1, 2024 through May 31, 2026, will support research to investigate the role of SMAD1/5/8 signaling in hepatocytes and hepatic stellate cells (HSCs) in liver fibrosis. The...
The U.S. Department of Health and Human Services' National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $361,400 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oncotrap Inc. The funding supports the development of a bispecific single-domain antibody targeting the chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis (NASH). The award will enable Oncotrap to generate a human version...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to The Regents of the University of California, San Francisco (UCSF). The $246,000 award, effective August 19, 2024 through June 30, 2026, will support the development of novel genetic tools for studying type IV collagens. The goal is to create mouse models that enable visualization and biochemical...
This $1,145,486 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop novel peripherally acting CB1 neutral antagonists for the treatment of diabetic kidney disease (DKD). The awardee, Makscientific LLC, a for-profit R&D company, will design and synthesize new analogs of compound AM6588 to improve potency, selectivity, oral...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $725,420 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop an optimized allysine-targeted positron emission tomography (PET) probe and validate it in animal models and human renal biopsy samples. The goal is to establish a non-invasive...
This federal Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the carbohydrate responsive element binding protein (ChREBP) and its isoforms in liver metabolism, metabolic diseases, and associated steatohepatitis. The $626,429 award, effective from July 1, 2025 to May 31, 2030, will employ genetic interventions...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $629,249 to the University of Alabama at Birmingham (UAB) to conduct research on a novel small molecule TXNIP inhibitor, TIX100, as a potential therapeutic for metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH). The research aims to determine the...